Apnimed snags $25m Series B
Apnimed, a developer of pharmacologic treatments for sleep apnea and related disorders, has raised $25 million in Series B financing.
Apnimed, a developer of pharmacologic treatments for sleep apnea and related disorders, has raised $25 million in Series B financing.
Copyright PEI Media
Not for publication, email or dissemination